AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Dose-finding Phase IIb Study With AZD0865 and Esomeprazole in GERD Patients With Erosive Esophagitis.
Phase 2
Completed
- Conditions
- GERD With Erosive Esophagitis
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2013-01-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1400
- Registration Number
- NCT00206245
- Locations
- 🇬🇧
Research Site, Woking, United Kingdom
🇸🇪Research Siteq, Östersund, Sweden
Immediate Release (IR) to Sustained Release (SR) Switching Study: Study of Switching From IR Seroquel to SR Seroquel in Outpatients With Schizophrenia
Phase 3
Completed
- Conditions
- Schizophrenia
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2013-01-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 454
- Registration Number
- NCT00206128
- Locations
- 🇪🇸
Research Site, Villamartin, Spain
🇱🇹Research Sitte, Vilnius, Lithuania
🇩🇪Research Center, Aachen, Nordrhein-Westfalen, Germany
A Study to Examine the Long Term Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2015-06-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 210
- Registration Number
- NCT00189514
- Locations
- 🇺🇸
Research Site, Olympia, Washington, United States
Efficacy and Safety of Oral Roflumilast Taken With Low Dose Inhaled Corticosteroids in Patients With Asthma (12 to 70 y) (BY217/M2-013)
Phase 3
Completed
- Conditions
- Asthma
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2016-12-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2054
- Registration Number
- NCT00163527
- Locations
- 🇬🇧
ALTANA Pharma, Cities in the United Kindom, United Kingdom
Safety of Ciclesonide Nasal Spray Administered With Inhaled Fluticasone Dipropionate/Salmeterol in Adults With Perennial Allergic Rhinitis (BY9010/M1-409)
Phase 3
Completed
- Conditions
- Perennial Allergic RhinitisAllergic RhinitisHay Fever
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2016-12-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 106
- Registration Number
- NCT00163488
- Locations
- 🇺🇸
Altana Pharma/Nycomed, Long Beach, California, United States
Efficacy of Ciclesonide Versus Budesonide in Patients With Asthma (18 to 75 y) (BY9010/M1-137)
Phase 3
Completed
- Conditions
- Asthma
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2016-11-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 120
- Registration Number
- NCT00163397
- Locations
- 🇨🇳
Altana Pharma/Nycomed, Taipei, Taiwan
Efficacy of Ciclesonide Inhaled Once Daily Versus Fluticasone Propionate Inhaled Twice Daily in Children With Asthma (6 to 11 y) (BY9010/M1-206)
Phase 3
Completed
- Conditions
- Asthma
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2016-12-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 750
- Registration Number
- NCT00163462
- Locations
- 🇿🇦
Altana Pharma/Nycomed, Wynberg, South Africa
Efficacy of Ciclesonide vs Fixed Combination of Fluticasone Propionate/Salmeterol vs Placebo in Patients With Mild Persistent Asthma (12 to 75 y) (BY9010/M1-132)
Phase 3
Completed
- Conditions
- Asthma
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2016-11-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 630
- Registration Number
- NCT00163358
- Locations
- 🇪🇸
Altana Pharma/Nycomed, Valencia, Spain
Efficacy and Safety of Roflumilast Taken in the Morning or Evening in Patients With Stable Asthma (12 to 70 y) (BY217/M2-015)
Phase 3
Completed
- Conditions
- Asthma
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2016-10-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 511
- Registration Number
- NCT00163475
- Locations
- 🇪🇸
ALTANA Pharma, Cities in Spain, Spain
Effects of Inhaled Ciclesonide Versus Fluticasone Propionate Versus Placebo on Lower Leg Growth in Prepubertal Children With Mild Persistent Asthma (6 to 12 y) (BY9010/M1-208)
Phase 3
Completed
- Conditions
- Asthma
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2016-12-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 28
- Registration Number
- NCT00163371
- Locations
- 🇩🇰
Altana Pharma/Nycomed, Kolding, Denmark
© Copyright 2025. All Rights Reserved by MedPath